These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Coumarin-pyrazoline Hybrids as Selective Inhibitors of the Tumor-associated Carbonic Anhydrase IX and XII.
    Author: Redij A, Carradori S, Petreni A, Supuran CT, Toraskar MP.
    Journal: Anticancer Agents Med Chem; 2023; 23(10):1217-1223. PubMed ID: 36825712.
    Abstract:
    AIM: Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated antitumor/ antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act as isoform-selective inhibitors of these isoforms over the cytosolic and mitochondrial ones. METHODS: We report the synthesis and in vitro CA inhibitory evaluation of a large panel of coumarins incorporating pyrazole-1-carboxamide moieties. Compounds were fully characterized before the assessment of their inhibitory activity. A stopped-flow CO2 hydrase assay was performed for the biological test. RESULTS: These coumarins did not inhibit the widespread, off-target isoforms CA I and II (KI >50 μM), but they were sub-micromolar CA IX/XII inhibitors with an interesting selectivity index higher than the reference compound. Selectivity between α- and β-class of CAs was also promising. CONCLUSION: These compounds may be used as leads for the rational design and development of non-sulfonamide CA IX/XII effective inhibitors.
    [Abstract] [Full Text] [Related] [New Search]